Company Overview

Agilent Technologies, Inc. is a global life sciences, diagnostics, and applied chemical analysis company that provides instruments, software, services, and consumables used in laboratories worldwide. The company operates primarily in the life sciences, diagnostics, and applied markets, supporting customers in pharmaceuticals, biotechnology, clinical diagnostics, chemical analysis, environmental testing, food safety, academia, and government research. Agilent’s core value proposition centers on high-precision measurement technologies, recurring consumables revenue, and long-term customer relationships tied to regulated laboratory environments.

The company’s primary revenue drivers include analytical instruments, laboratory consumables such as chromatography columns and reagents, diagnostic solutions, and ongoing service contracts. Agilent is known for strong installed-base economics, where instrument sales drive recurring consumables and services revenue over extended product lifecycles. The company was founded in 1999 as a spin-off from Hewlett-Packard’s measurement businesses and has since evolved into a focused life sciences and diagnostics platform through organic investment and targeted acquisitions, including the expansion into clinical and companion diagnostics.

Business Operations

Agilent generates revenue through three primary operating segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. Life Sciences and Applied Markets provides analytical instruments such as liquid chromatography, gas chromatography, mass spectrometry, spectroscopy, and related software, primarily serving pharmaceutical, chemical, energy, environmental, and academic laboratories. Diagnostics and Genomics focuses on pathology, genomics, nucleic acid solutions, and companion diagnostics used in clinical and research settings.

Agilent CrossLab delivers laboratory services, consumables, and compliance solutions, including instrument services, asset management, laboratory software, and workflow optimization. This segment is a key contributor to recurring revenue and customer retention. Agilent operates manufacturing, R&D, sales, and service organizations globally and maintains a direct sales force complemented by distributors in certain international markets. The company also manages regulated diagnostic operations that require compliance with regional healthcare and laboratory standards.

Strategic Position & Investments

Agilent’s strategy emphasizes high-growth life sciences end markets, expansion of recurring revenue streams, and disciplined capital allocation. The company has invested significantly in companion diagnostics, cell analysis, and advanced analytical platforms that support biologics, genomics, and precision medicine workflows. Strategic acquisitions have been used to expand capabilities and address adjacent markets, including the acquisition of Resolution Bioscience to strengthen next-generation sequencing-based oncology diagnostics and BioTek Instruments to enhance cell analysis and laboratory automation offerings.

The company continues to invest in software-enabled workflows, automation, and digital laboratory solutions to increase customer productivity and embed Agilent technologies deeper into customer operations. Agilent also maintains a portfolio of diagnostic partnerships with pharmaceutical companies to co-develop companion diagnostics aligned with targeted therapies, reinforcing its position at the intersection of research and clinical application.

Geographic Footprint

Agilent operates on a global scale, with its corporate headquarters located in North America (United States). The company maintains significant commercial and operational presence across North America, Europe, and Asia-Pacific, with additional operations serving Latin America and other international markets. Revenue is geographically diversified, with no single non-U.S. country dominating overall sales.

Manufacturing, research and development, and service centers are strategically distributed across key regions to support local market needs, regulatory requirements, and supply chain resilience. Agilent’s international footprint enables it to serve multinational pharmaceutical companies, global research institutions, and regional diagnostic laboratories, while also supporting emerging market growth through localized sales and service infrastructure.

Leadership & Governance

Agilent is led by an experienced executive team with deep backgrounds in life sciences, diagnostics, and industrial technology. The leadership team emphasizes operational discipline, innovation, and long-term value creation, with a strategic focus on recurring revenue, customer-centric solutions, and disciplined investment aligned with regulated end markets.

Key executives include:

• Padraig McDonnell – President and Chief Executive Officer
• Bob McMahon – Senior Vice President and Chief Financial Officer
• Mike McGettrick – Senior Vice President and President, Life Sciences and Applied Markets
• Sheila Sadik – Senior Vice President and President, Diagnostics and Genomics
• Mark Doak – Senior Vice President, Agilent CrossLab
• Jeannine Sargent – Senior Vice President, Human Resources

The company operates under a board-governed structure typical of large publicly traded U.S. corporations, with executive compensation, risk oversight, and strategic direction aligned with long-term shareholder and stakeholder interests.